Vaccines

Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates

Retrieved on: 
Thursday, August 22, 2019

Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis measles virus vector-based platform.

Key Points: 
  • Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis measles virus vector-based platform.
  • We are excited to collaborate with MSD and to develop a vaccine that has the potential to provide a significant benefit to a great number of patients worldwide.
  • Under the terms of the agreement, Themis will develop vaccine candidates against an undisclosed disease target.
  • MSD will provide research funding and make an equity investment in Themis.

Emerging Trends, Drivers and Challenges in the Global Pediatric Vaccine Market 2019-2023 | Technavio

Retrieved on: 
Tuesday, August 20, 2019

The global pediatric vaccine market size is poised to grow by USD 10.76 billion during 2019-2023, according to a new report by Technavio, progressing at a CAGR of over 7% during the forecast period.

Key Points: 
  • The global pediatric vaccine market size is poised to grow by USD 10.76 billion during 2019-2023, according to a new report by Technavio, progressing at a CAGR of over 7% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20190820005470/en/
    Technavio has announced its latest market research report titled global pediatric vaccine market 2019-2023.
  • Also, the increasing prevalence of infectious diseases in the pediatric population will further boost the growth of the pediatric vaccine market.
  • Thus, the increasing prevalence of infectious diseases in the pediatric population will increase the demand for pediatric vaccines during the forecast period.

Global Pneumococcal Vaccines Market Predicted to Grow with a CAGR of 3.3% During the Forecast Period, 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 20, 2019

The report predicts the global pneumococcal vaccines market to grow with a CAGR of 3.3% over the forecast period from 2019-2025.

Key Points: 
  • The report predicts the global pneumococcal vaccines market to grow with a CAGR of 3.3% over the forecast period from 2019-2025.
  • The report on the global pneumococcal vaccines market provides qualitative and quantitative analysis for the period from 2017 to 2025.
  • The report on pneumococcal vaccines market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pneumococcal vaccines market over the period of 2017 to 2025.
  • Complete coverage of all the segments in the pneumococcal vaccines market to analyze the trends, developments in the global market and forecast of market size up to 2025.

Global Cervical Cancer Vaccines Market to Surpass US$ 6 Billion by 2026

Retrieved on: 
Thursday, August 22, 2019

Key Trends and Analysis of the Global Cervical Cancer Vaccines Market:

Key Points: 
  • Key Trends and Analysis of the Global Cervical Cancer Vaccines Market:
    The cervical cancer vaccines market size is expected to witness significant growth in the forecast period, owing to increasing government initiatives regarding cervical cancer vaccines.
  • The global cervical cancer vaccines market is projected to witness a CAGR of 12.1% during the forecast period (2018 2026), owing to development of affordable vaccines for the prevention of cervical cancer in low- and middle-income countries.
  • Major players operating in the global cervical cancer vaccines market include, GlaxoSmithKline plc.
  • and Merck & Co. Inc.
    To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/cervical-cancer-va...
    Global Cervical Cancer Vaccines Market , By Product Type:

Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference

Retrieved on: 
Thursday, August 22, 2019

SUMMIT, N.J., Aug. 22, 2019 /PRNewswire/ --Seqirus, a global leader in influenza prevention, today announced it will feature data in 3 presentations and 24 posters on the company's adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

Key Points: 
  • SUMMIT, N.J., Aug. 22, 2019 /PRNewswire/ --Seqirus, a global leader in influenza prevention, today announced it will feature data in 3 presentations and 24 posters on the company's adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.
  • "We look forward to sharing our latest data at OPTIONS X and continuing to develop our broad portfolio of vaccines to help reduce the burden of disease caused by influenza."
  • Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.
  • Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies.

The Contract Manufacturing Services Market for Vaccines is Expected to Grow at an Annualized Rate of Over 10%, Claims Roots Analysis

Retrieved on: 
Tuesday, August 20, 2019

LONDON, Aug. 20, 2019 /PRNewswire/ -- Roots Analysis has announced the addition ofthe " Vaccine Contract Manufacturing Market (2nd Edition), 2019- 2030 " report to its list of offerings.

Key Points: 
  • LONDON, Aug. 20, 2019 /PRNewswire/ -- Roots Analysis has announced the addition ofthe " Vaccine Contract Manufacturing Market (2nd Edition), 2019- 2030 " report to its list of offerings.
  • Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines.
  • Interestingly, stakeholders are mainly focused on manufacturing vaccines against infectious diseases, followed by oncology and respiratory diseases.
  • The financial opportunity of over USD 4 billion (by 2030) within the vaccine contract manufacturing market has been analyzed across the following segments:

The Contract Manufacturing Services Market for Vaccines is Expected to Grow at an Annualized Rate of Over 10%, Claims Roots Analysis

Retrieved on: 
Tuesday, August 20, 2019

LONDON, Aug. 20, 2019 /PRNewswire/ -- Roots Analysis has announced the addition ofthe " Vaccine Contract Manufacturing Market (2nd Edition), 2019- 2030 " report to its list of offerings.

Key Points: 
  • LONDON, Aug. 20, 2019 /PRNewswire/ -- Roots Analysis has announced the addition ofthe " Vaccine Contract Manufacturing Market (2nd Edition), 2019- 2030 " report to its list of offerings.
  • Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines.
  • Interestingly, stakeholders are mainly focused on manufacturing vaccines against infectious diseases, followed by oncology and respiratory diseases.
  • The financial opportunity of over USD 4 billion (by 2030) within the vaccine contract manufacturing market has been analyzed across the following segments:

DTP Vaccine Associated with Increased Rate of Total Mortality in Low-Income Countries Says Peter Gøtzsche in New Expert Report

Retrieved on: 
Friday, August 16, 2019

In 2012, SAGE requested that the WHO review the evidence concerning the possible effects of DTP vaccines on mortality1.

Key Points: 
  • In 2012, SAGE requested that the WHO review the evidence concerning the possible effects of DTP vaccines on mortality1.
  • In a new expert report, Peter C. Gtzsche, Professor, DrMedSci, MSc analyzed the WHO systematic review as well as any studies published after the WHO report that assessed the effect of DTP vaccine on total mortality.
  • This new expert report concludes that the "evidence tells us that it is likely that the DTP vaccine increases total mortality in low-income countries."
  • "No one should be offered this vaccine without full informed consent that includes information that the vaccine is likely to increase total mortality.

Four Distinguished Global Leaders Join the Human Vaccines Project's Efforts to Decode the Human Immune System

Retrieved on: 
Thursday, August 15, 2019

NEW YORK, Aug. 15, 2019 /PRNewswire/ -- Four distinguished global leaders are joining the Human Vaccines Project to help push forward its effort to solve one the greatest public health challenges of the 21st century, the decoding of the human immune system.

Key Points: 
  • NEW YORK, Aug. 15, 2019 /PRNewswire/ -- Four distinguished global leaders are joining the Human Vaccines Project to help push forward its effort to solve one the greatest public health challenges of the 21st century, the decoding of the human immune system.
  • "The Human Vaccines Project is very pleased that these four accomplished leaders have embraced the Project's mission to address the next frontier in human health, the human immune system," says Wayne C. Koff, Ph.D., President and CEO of the Human Vaccines Project.
  • The Human Vaccines Project is a bold public-private initiative that aims to decode the human immune system to make the next leap forward in human health.
  • Pioneering a new era in health, the Project will enable the creation of next-generation vaccines, diagnostics, and therapies across diseases.

Novavax Scientific Leadership to Present New RSV Maternal Immunization Program Phase 3 Data and Participate in Discussion on RSV at the 2019 IDSOG Annual Meeting

Retrieved on: 
Thursday, August 8, 2019

ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant.

Key Points: 
  • ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant.
  • It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life.
  • In February 2019, Novavax announced top-line data from Prepare, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants.
  • Novavax is also advancing NanoFlu, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines.